Incyte Corporation (INCY)
NASDAQ: INCY · Real-Time Price · USD
102.52
+2.06 (2.05%)
At close: Dec 5, 2025, 4:00 PM EST
102.55
+0.03 (0.03%)
After-hours: Dec 5, 2025, 7:33 PM EST
Incyte Employees
Incyte had 2,617 employees as of December 31, 2024. The number of employees increased by 93 or 3.68% compared to the previous year.
Employees
2,617
Change (1Y)
93
Growth (1Y)
3.68%
Revenue / Employee
$1,839,169
Profits / Employee
$454,178
Market Cap
20.13B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2,617 | 93 | 3.68% |
| Dec 31, 2023 | 2,524 | 200 | 8.61% |
| Dec 31, 2022 | 2,324 | 230 | 10.98% |
| Dec 31, 2021 | 2,094 | 321 | 18.10% |
| Dec 31, 2020 | 1,773 | 317 | 21.77% |
| Dec 31, 2019 | 1,456 | 89 | 6.51% |
| Dec 31, 2018 | 1,367 | 159 | 13.16% |
| Dec 31, 2017 | 1,208 | 228 | 23.27% |
| Dec 31, 2016 | 980 | 288 | 41.62% |
| Dec 31, 2015 | 692 | 104 | 17.69% |
| Dec 31, 2014 | 588 | 107 | 22.25% |
| Dec 31, 2013 | 481 | 68 | 16.46% |
| Dec 31, 2012 | 413 | 45 | 12.23% |
| Dec 31, 2011 | 368 | 121 | 48.99% |
| Dec 31, 2010 | 247 | 26 | 11.76% |
| Dec 31, 2009 | 221 | 9 | 4.25% |
| Dec 31, 2008 | 212 | 16 | 8.16% |
| Dec 31, 2007 | 196 | 10 | 5.38% |
| Dec 31, 2006 | 186 | 9 | 5.08% |
| Dec 31, 2005 | 177 | -9 | -4.84% |
| Dec 31, 2004 | 186 | -268 | -59.03% |
| Dec 31, 2003 | 454 | -37 | -7.54% |
| Dec 31, 2002 | 491 | -94 | -16.07% |
| Dec 31, 2001 | 585 | -737 | -55.75% |
| Dec 31, 2000 | 1,322 | 214 | 19.31% |
| Dec 31, 1999 | 1,108 | 241 | 27.80% |
| Dec 31, 1998 | 867 | 191 | 28.25% |
| Dec 31, 1997 | 676 | 218 | 47.60% |
| Dec 31, 1996 | 458 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
INCY News
- 1 hour ago - Incyte: Buy At This Inflection Point - Seeking Alpha
- 2 days ago - Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 days ago - Incyte Corporation (INCY) Presents at Evercore 8th Annual Healthcare Conference Transcript - Seeking Alpha
- 3 days ago - Global Vitiligo Foundation Applauds Partnership Between Incyte and Winnie Harlow to Elevate Awareness and Understanding of Vitiligo - Business Wire
- 3 days ago - Incyte Corporation (INCY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 4 days ago - Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding - Business Wire
- 5 days ago - Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel - Business Wire
- 9 days ago - Incyte: This Profitable Biotech Trades Like A Melting Iceberg - Seeking Alpha